21 completed, 3 recruiting, 2 not yet recruiting, 1 active not recruiting. 15 Phase 3, 2 Not applicable, 1 Phase 2.
By phase and status
Follow Hepatitis C Virus (HCV): new trials by email Literature Review of Hepatitis C Virus (HCV) trials Research Report on Hepatitis C Virus (HCV)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Assessing Performance of a Hepatitis C Emergency Department (HepC-EnD) Screening Tool: IT Integration Process for Electronic Health Record System Physician-Initiated Screening (Conventional Screening), FOCUS (Universal Screening), HepC-EnD (Targeted Screening) - Hepatitis C Virus (HCV), Hepatitis C Virus (HCV) Infection Not yet recruiting University of Florida 6466 2026-07-01 2026-04-29 MAGIA H3S Point of Care Test Performance for HIV, HBV, HCV, and Syphilis Screening in Pregnant Women in DR Congo MAGIA H3S - HIV - Human Immunodeficiency Virus, HBV (Hepatitis B Virus) Not yet recruiting Gardiens de Vies 7500 2026-03-01 2026-02-05 Study of Glecaprevir/Pibrentasvir to Assess Safety Through Real-World Data Hepatitis C Virus (HCV) Recruiting AbbVie 2000 2026-02-27 2026-04-16 California MEPS Hub Mobile Enhanced Prevention Support (MEPS), Control - HIV Prevention, Sexually Transmitted Infections (STI) Not applicable Recruiting University of California, Los Angeles 318 2025-12-01 2026-04-03 Enhancing Uptake of Needle and Syringe Programs in Canadian Federal Prisons NIATx - HIV, Hepatitis C Virus (HCV) Not applicable Recruiting McGill University Health Centre/Research Institute of the McGill University Health Centre 548 2024-10-01 2025-12-29 Sofosbuvir/Velpatasvir/Voxilaprevir Salvage Therapy in Hepatitis C Patients Who Relapsed After DAA Treatment Hepatitis C Virus (HCV) Active not recruiting Xiangya Hospital of Central South University 200 2022-01-01 2026-05-04 Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) Glecaprevir/Pibrentasvir (GLE/PIB) - Hepatitis C Virus (HCV) Phase 3 Completed AbbVie 286 2021-08-24 2025-04-06 Study of Oral Glecaprevir/Pibrentasvir Tablets in Participants Aged 12 Years or Older With Chronic Hepatitis C to Assess Sustained Virological Response Hepatitis C Virus (HCV) Completed AbbVie 42 2020-10-07 2023-08-14 Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years and Older) And Adult Treatment-Naive Participants With Chronic Hepatitis C Genotypes 1 To 6 And Liver Cirrhosis Hepatitis C Virus (HCV) Completed AbbVie 99 2020-05-29 2022-06-09 A Study Describing the Care Cascade and Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adult Participants With Hepatitis C Virus in French Addiction Centers Hepatitis C Virus (HCV) Completed AbbVie 95 2020-05-26 2024-02-01 A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation Hepatitis C Virus (HCV) Completed AbbVie 99 2020-02-17 2022-06-27 A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus Hepatitis C Virus (HCV) Completed AbbVie 50 2019-12-26 2025-07-20 A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection Glecaprevir/Pibrentasvir - Hepatitis C Virus (HCV) Phase 3 Completed AbbVie 100 2018-06-06 2020-03-17 Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6 Hepatitis C Virus (HCV) Completed AbbVie 1095 2017-12-27 2021-09-20 A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection Placebo, Glecaprevir/Pibrentasvir - Hepatitis C Virus (HCV) Phase 3 Completed AbbVie 546 2017-10-04 2019-12-23 Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection Glecaprevir/Pibrentasvir - Hepatitis C Virus (HCV) Phase 3 Completed AbbVie 160 2017-09-29 2019-11-21 A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs Hepatitis C Virus (HCV) Completed AbbVie 505 2017-08-17 2020-10-08 Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1 Glecaprevir/Pibrentasvir - Hepatitis C Virus (HCV) Phase 3 Completed AbbVie 230 2017-08-07 2019-09-04 A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis Glecaprevir/Pibrentasvir - Hepatitis C Virus (HCV) Phase 3 Completed AbbVie 343 2017-04-28 2020-07-13 A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment Glecaprevir/pibrentasvir - Hepatitis C Virus (HCV) Phase 3 Completed AbbVie 101 2017-03-28 2019-03-04
Showing 20 of 28. Sign in to see all of them.
Narrower conditions Hepatitis C (28) · Hepatitis C, Chronic (11) · Acquired Immunodeficiency Syndrome (4) · Fibrosis (4) · Coinfection (2) · Renal Insufficiency, Chronic (2) · Bronchiolitis Obliterans Syndrome (1) · Emergencies (1) · Hepatitis (1) · Hepatitis B (1) · Infections (1) · Kidney Diseases (1) · Liver Cirrhosis (1) · Sexually Transmitted Diseases (1) · Substance-Related Disorders (1)
Broader conditions Blood-Borne Infections (28) · Communicable Diseases (28) · Digestive System Diseases (28) · Flaviviridae Infections (28) · Hepatitis, Viral, Human (28) · Liver Diseases (28) · RNA Virus Infections (28) · Virus Diseases (28) · Hepatitis (27) · Infections (27) · Pathologic Processes (15) · Pathological Conditions, Signs and Symptoms (15) · Disease Attributes (14) · Chronic Disease (12) · Hepatitis, Chronic (11)
Interventions glecaprevir and pibrentasvir (9) · Ribavirin (4) · glecaprevir (4) · Viekira Pak (3) · dasabuvir (3) · ombitasvir (3) · paritaprevir (3) · peginterferon alfa-2a (3) · peginterferon lambda-1a (3) · pibrentasvir (3) · Standard of Care (1) · daclatasvir (1)
Sponsors AbbVie (20) · Bristol-Myers Squibb (3) · Gardiens de Vies (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · University of California, Los Angeles (1) · University of Florida (1) · Xiangya Hospital of Central South University (1)
Countries United States (10) · Canada (9) · Russia (8) · South Korea (7) · France (6) · Spain (6) · United Kingdom (5) · China (4) · Germany (4) · Italy (4) · Japan (4) · Poland (4) · Puerto Rico (4) · Singapore (4) · Australia (3)
Top investigators Frederick L. Altice (1) · Haesuk Park, PhD (1) · Huang Yan, Professor (1) · Nadine Kronfli (1)
Results publications PMID 35174470 , PMID 32682494 , PMID 29909549 , PMID 30291369 , PMID 30980576 , PMID 31254392 , PMID 31646465 , PMID 31682879 , PMID 31821716 , PMID 32949786 , PMID 33811356 , PMID 41297677 , PMID 42189498 , PMID 42340583
NIH funding 2016 (5), 2015 (1), R01DA057886 (1), R33DA060626 (1)